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ABSTRACT
Human ribonuclease-1 (hRNase-1) is an extracellular
enzyme found in exocrine pancreas, blood, milk,
saliva, urine and seminal plasma, which has been
implicated in digestion of dietary RNA and in antiviral
host defense. The enzyme is characterized by a high
catalytic activity toward both single-stranded and
double-stranded RNA. In this study, we explored
the possibility that hRNase-1 may also be provided
with a ribonuclease H activity, i.e. be able to digest
the RNA component of RNA:DNA hybrids. For this
purpose, we developed an accurate and sensitive
real-time RNase H assay based on a fluorogenic
substrate made of a 12 nt 50-fluorescein-labeled
RNA hybridized to a complementary 30-quencher-
modified DNA. Under physiological-like conditions,
hRNase-1 was found to cleave the RNA:DNA
hybrid very efficiently, as expressed by a kcat/Km of
330 000 M
 1 s
 1, a value that is over 180-fold higher
than that obtained with the homologous bovine
RNase A and only 8-fold lower than that measured
with Escherichia coli RNase H. The kinetic character-
izationofhRNase-1showedthatitshybridaseactivity
ismaximalatneutralpH,increaseswithloweringionic
strength and is fully inhibited by the cytosolic RNase
inhibitor. Overall, the reported data widen our knowl-
edge of the enzymatic properties of hRNase-1 and
provide new elements for the comprehension of its
biological function.
INTRODUCTION
Human ribonuclease-1 (hRNase-1), also known as human
pancreatic ribonuclease, is a basic protein of 128 amino
acid residues (1,2). It belongs to the superfamily of extracel-
lular ribonucleases of tetrapods (3) that counts eight members
in humans (4). The enzyme represents the human counterpart
of the well-known bovine pancreatic RNase A (5,6) with
which it shares 70% sequence identity and the ability to
cleave RNA speciﬁcally on the 30 side of pyrimidine bases
(7). Despite the high degree of sequence identity, hRNase-1
differentiates from the bovine enzyme for a very high activity
toward double-stranded RNA (dsRNA) (8). Under
physiological-like conditions, the kcat/Km of hRNase-1 for
cleavage of the homopolymeric substrate poly(rA):poly(rU)
is 148 500 M
 1 s
 1, a value that is  500-fold higher than
that measured with RNase A (9). The activity of the human
enzyme toward single-stranded RNA (ssRNA) is instead
few-fold lower than that of RNase A. Few other members
of the ribonuclease superfamily are able to digest dsRNA
but less efﬁciently than hRNase-1. Among them, whale pan-
creas RNase whose activity towards poly(rA):poly(rU) is
 10-fold lower than that of hRNase-1 (8). Mutational studies
have shown that the potent activity of hRNase-1 on dsRNA is
related to the presence of noncatalytic basic residues which
cooperatively contribute to the binding and destabilization
of the double-helical RNA molecule (9).
Human RNase-1 is expressed at high levels in exocrine
pancreas and in endothelial cells (10,11), from which it is
believed to be secreted in duodenum and in blood plasma,
respectively. Plasma concentration of hRNase-1 has been
estimated to be  0.4 mg/l (11). The enzyme is also expressed
in testis, ovary, brain, mammary gland and other tissues
(10,12), and is found in other body ﬂuids such as milk,
urine, saliva and seminal plasma (13–15). The fraction of
hRNase-1 that is produced by the pancreas is likely responsi-
ble for the digestion of dietary RNA (16) whereas the
hRNase-1 found in blood plasma and in the other body ﬂuids
plays a role yet to be assessed.
Many viruses have dsRNA genomes or ssRNA genomes
that replicates through dsRNA intermediates. These include
ﬂavivirus, picornavirus and inﬂuenza virus whose replication
is assisted by an RNA-dependent RNA polymerase.
Mammals have evolved a variety of defense mechanisms
in response to exposition to dsRNA. These include the
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doi:10.1093/nar/gkl368interferon system and the intracellular degradation of dsRNA
operated by Dicer (17). Since hRNase-1 is very effective in
digesting dsRNA and since is present in blood and other
body ﬂuids, it has been proposed that the enzyme plays an
antiviral role (9,11). In this regard, other human extracellular
ribonucleases have been found recently to play not-digestive
roles and to be involved in host defense. Human RNase-
3 (also named eosinophil cationic protein) (18) has
helminthotoxic and anti-bacterial activity (19,20) and
hRNase-7 from human skin has a very potent antimicrobial
activity against various pathogenic microorganisms, includ-
ing Staphylococcus aureus, Pseudomonas aeruginosa,
Propionibacterium acnes and Candida albicans (21). It
should also be noted that hRNase-1 has been shown to
suppress the replication of HIV in cultured lymphocytes (22).
A wider characterization of the enzymatic properties of
hRNase-1 may provide new elements for the comprehension
of the biological function of the enzyme. Given the peculiar
ability of hRNase-1 to bind and cleave dsRNA, we consid-
ered another double-helical substrate, an RNA:DNA hybrid
and tested the enzyme for ribonuclease H activity (23,24),
i.e. for the ability to digest the RNA component of
RNA:DNA hybrids.
MATERIALS AND METHODS
Materials and general procedures
Water, buffers and salt solutions were made RNase-free by
ﬁltration through a Sep-Pak C18 column (Waters) activated
with 5 ml of methanol. Acetylated BSA, RNase A and
human plasma were obtained from Sigma. RNase A was quan-
tiﬁed spectrophotometrically using a e278 value of 9800 M
 1
cm
 1 (25). Human RNase-1 was obtained from a recombi-
nant expression system in Escherichia coli (26) and stored
in 0.1 M Tris–HCl (pH 8.0), containing 0.3 M NaCl, as it
is poorly soluble at low ionic strength. The stock concentra-
tion of hRNase-1 was determined by amino acid analysis.
Cytosolic RNase inhibitor was obtained from Promega.
E.coli RNase H was from USB. Its stock concentration was
5U / ml, which is equivalent to 12 ng/ml (27). Fluorescence
measurements were carried out on a Perkin-Elmer LS50B
Luminescence Spectrometer equipped with semimicro
(1.5 ml) glass cuvettes. Ion-pair reversed-phase high pressure
liquid chromatography (HPLC) of oligonucleotides was
performed using a Symmetry  C18 column (Waters) ther-
mostated at 65 C and a 13 min linear gradient of acetonitrile
concentration from 10 to 40% in 0.1 M triethylammonium
acetate (pH 7.0), at a ﬂow rate of 0.9 ml/min. The absorbance
was monitored at 260 nm.
Preparation of the substrate
The RNA strand, ﬂuorescein-50-rA-rA-rC-rA-rG-rG-rA-rG-
rG-rA-rG-rG-30 and the DNA strand, 50-dC-dC-dT-dC-dC-
dT-dC-dC-dT-dG-dT-dT-30-dabcyl, were custom synthesized
on a 1 mmol scale by MWG Biotech. Brieﬂy, the RNA oligo
was prepared via the 50-silyl-20-acetoxy ethyl orthoester
chemistry, puriﬁed by polyacrylamide gel electrophoresis,
and provided in the stable 20-orthoester protected form. It
was then deprotected by mild acidic treatment, according to
the manufacturer’s instructions, and quantiﬁed spectrophoto-
metrically using a e260 value of 154 700 M
 1 cm
 1.T h e
DNA oligo was synthesized by standard phosphoramidite
chemistry, puriﬁed by reversed-phase HPLC and quantifed
using a e260 value of 102 700 M
 1 cm
 1. The two oligonu-
cleotides were then mixed at 10 mM concentration each in
50 mM Tris–HCl (pH 7.4), containing 50 mM KCl, heated
at 80 C for 5 min, and cooled at room temperature over a
2 h period to allow hybrid formation. The resulting substrate
solution was stored in aliquots at  20 C.
Enzyme kinetics
Hybridase assays were performed at 37 C in 1 ml of the spe-
ciﬁed buffer containing 10–400 nM RNA:DNA hybrid. Initial
rates of substrate cleavage were determined by measuring the
rate of change in ﬂuorescence intensity at 520 nm upon
excitation at 490 nm. Initial rates in units of ﬂuorescence
intensity per second were converted to moles per liter per
second by dividing by the maximum change in ﬂuorescence
intensity and multiplying by the initial concentration of the
substrate. The maximum change in ﬂuorescence intensity
for each substrate concentration and pH was obtained by
incubation with a large excess of the enzyme under testing.
Initial rates were determined by considering only those
portions of the reaction progress curves that yielded <7% of
substrate cleavage. Values of kcat/Km were calculated from
the equation kcat/Km ¼ V0/[E][S] by measuring the initial
rates of reaction at a substrate concentration, 10 nM, that is
well below Km of all the enzymes tested. This was veriﬁed
by running control assays at 3- to 4-fold higher substrate con-
centrations that yielded proportionally increased V0 values.
Ribonucleolytic assays toward the isolated RNA strand of
the hybrid were performed in 100 ml of 40 mM Tris–HCl
(pH 7.4), containing 60 mM NaCl, 60 mM KCl, 20 mg/ml
BSA, 1 mM ﬂuorescein-50-rA-rA-rC-rA-rG-rG-rA-rG-rG-rA-
rG-rG-30 and 0.3 nM hRNase-1. After 20–40 min of
incubation at 37 C, substrate and products were quantiﬁed
by ion-pair reversed-phase HPLC, performed as described
in Materials and Methods except that the acetonitrile gradient
ranged from 10 to 15% in 5 min. Values of kcat/Km were then
calculated from the formula kcat/Km ¼ ln ([S0]/[S])/t[E], were
[S0] and [S] are substrate concentrations at the initial time and
time t, respectively. The reported value of kcat/Km of hRNase-
1 for cleavage of the RNA strand is the mean ± SEM of
six measurements. Control assays at 3 mM substrate concen-
tration yielded values of kcat/Km undistinguishable from those
obtained at 1 mM.
RESULTS AND DISCUSSION
Design and preparation of a fluorogenic RNA:DNA
hybrid
Traditional methods for assaying ribonuclease H activity are
largely based on radiolabeled substrates and are discontinu-
ous (28,29). Assay systems for real-time detection of
RNase H activity have been developed only recently. In
2002, Rizzo et al. (27) reported an assay method for E.coli
RNase H based on the ﬂuorescence quenching mechanism
of molecular beacons. The substrate was a single-stranded
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homopolymeric 50-ﬂuorescein-oligo(rA) duplexed with
oligo(dT)-30-dabcyl. The ﬂuorophore of the substrate was
held in close proximity to the quencher (dabcyl) by the
RNA:DNA stem–loop structure. When the RNA sequence
of the RNA:DNA hybrid stem was cleaved, the ﬂuorophore
was separated from the quencher producing an increase in
ﬂuorescence. This assay permits accurate measurement of
RNase H activity but cannot be easily implemented since
the substrate is not commercially obtainable. It should also
be noted that the RNA component of this substrate, made
of poly(rA), doesn’t meet the substrate speciﬁcity of hRNase-
1 that cleaves at pyrimidine sites. In 2003, Parniak et al. (30)
reported a similar ﬂuorometric assay based on commercially
obtainable oligonucleotides. The substrate was a 18 nt 30-
ﬂuorescein-labeled RNA annealed to a complementary 18
nt 50-dabcyl-modiﬁed DNA. The RNA sequence, containing
eight pyrimidines, and the overall structure of this substrate
had been optimized for testing the HIV reverse transcriptase-
associated RNase H (30). This feature makes the assay poorly
suitable to kinetic studies with hRNase-1 because this
enzyme, if endowed with RNase H activity, will likely cleave
the substrate at the several pyrimidine sites making the mea-
surement of true kcat or kcat/Km values very difﬁcult.
In order to develop a real-time RNase H assay suitable to
test hRNase-1, we designed a new ﬂuorogenic substrate based
on commercially obtainable oligonucleotides and provided
with a single cleavable bond (Figure 1). The double-helical
hybrid is made of a 12 nt 50-fuorescein-labeled RNA
hybridized to a complementary 12 nt 30-dabcyl-modiﬁed
DNA. The melting temperature (Tm) of the hybrid was pre-
dicted to be 52 C, a value high enough to ensure a good sta-
bility of the secondary structure at the assay temperature
(37 C). This is important to minimize the baseline ﬂuores-
cence signal by ensuring that the ﬂuorophore and the
quencher stay in close proximity. The RNA strand of the
hybrid contains only one pyrimidine, three bases apart from
the 50 end, where the cleavage by hRNase-1 is expected to
occur (Figure 1). Upon cleavage, the resulting ﬂuorescein-
labeled trinucleotide is expected to dissociate readily from
the complementary DNA, producing a large increase in ﬂuo-
rescence emission at 520 nm upon excitation at 490 nm. On
the basis of these theoretical considerations, the two oligonu-
cleotides were custom synthesized, puriﬁed and annealed to
form the double-helical substrate.
Evaluation of the substrate with E.coli RNase H and
specificity tests
As a ﬁrst step in the evaluation of the newly prepared sub-
strate, an aliquot of it was excited at 490 nm and an emission
spectrum was recorded. As shown in Figure 2, emission at
520 nm is very weak, suggesting that the dabcyl efﬁciently
quenches the emission of the ﬂuorescein label. The substrate
was then treated with an excess of E.coli RNase H (31), used
as a positive control of the enzymatic reaction, and a new
spectrum was recorded (Figure 2). As shown, the complete
degradation of the substrate produced a large ﬂuorescence
enhancement, with an emission signal at 520 nm that is
19-fold higher than that of the intact substrate. This result
indicates that the substrate is suitable to test the enzymatic
activity of RNases H. Kinetic measurement were then
Figure 1. Structure of the fluorogenic RNA:DNA hybrid and principle of the ribonuclease H assay. In the intact substrate the fluorophore (fluorescein) and the
quencher(dabcyl)areincloseproximityandfluorescenceishencequenched.UponcleavageoftheRNAstrand,thefluorophoreisliberatedfromthehybrid,resulting
in a large increase in fluorescence.
Figure 2. Fluorescence emission spectra of the substrate and its cleavage
products. Spectra of the substrate before (dashed line) and after (solid line)
treatmentwithE.coliRNaseHwererecordedat37 Cwithexcitationat490nm.
Digestionhadbeenperformedin40mMTris–HCl(pH7.4),containing60mM
NaCl, 60 mM KCl, 2 mM MgCl2, 4 mM DTT, 20 mg/ml BSA, 10 nM substrate
and 1 nM E.coli RNase H, at 37 C for 1 h.
2908 Nucleic Acids Research, 2006, Vol. 34, No. 10performed at lower concentrations of E.coli RNase H, within
the pM range and ﬂuorescence was measured continuously
soon after the addition of the enzyme. As shown in
Figure 3, the resulting ﬂuorescence increases are time-
dependent and RNase H concentration-dependent. Each reac-
tion progress trace shows a good initial linearity and enzyme
concentrations as little as 28 pM can be easily assayed. This
enzyme concentration is at least 75-fold lower that those
tested in the previously reported molecular beacon assay for
E.coli RNase H (27). Overall, the kinetic data were used to
measure an apparent kcat/Km value of 2.54 · 10
6 M
 1 s
 1
(Table 1).
The speciﬁcity of the assay for RNase H activity was then
assessed by testing bovine RNase A, a potent hydrolase with
a known speciﬁcity for ssRNA (6). The assay of this enzyme
toward the double-helical hybrid revealed a barely detectable
activity with a kcat/Km of 1800 M
 1 s
 1 (Table 1), a value
 1400-fold lower than that measured with E.coli RNase H.
An additional control was then introduced by testing
bovine DNase I, a hydrolase known to cleave efﬁciently
both single-stranded and double-stranded DNA. With this
enzyme no ﬂuorescence enhancement could be detected
even at enzyme concentrations as high as 650 nM (data not
shown), giving additional support to the speciﬁcity of the
assay.
Overall, these data indicate that the newly developed
RNase H assay is accurate, sensitive and highly speciﬁc.
Testing of hRNase-1 was subsequently undertaken.
Testing of hRNase-1 for hybridase activity
Assays were performed under physiological-like conditions,
i.e. at 37 C in a solution buffered at pH 7.4 with an ionic
strength of 0.15 M. As shown in Figure 4, concentrations
of hRNase-1 in the low nM range were able to produce
large increases in ﬂuorescence emission. Measurement of
V0 values revealed a good correlation with enzyme concentra-
tions and yielded a kcat/Km of 330 000 M
 1 s
 1 (Table 1).
This value is over 180-fold higher than that obtained with
the homolog bovine RNase A and only 8-fold lower than
that measured with E.coli RNase H.
As a control, cleavage of the substrate by hRNase-1 was
also checked by a direct method. An aliquot of the double-
helical hybrid was partially digested with hRNase-1 and the
reaction mixture was analyzed by ion-pair reversed-phase
HPLC. Comparison of the resulting elution proﬁle with that
obtained with the intact substrate (Figure 5) conﬁrmed that
only the RNA component of the hybrid was affected by the
enzyme and revealed only two oligoribonucleotide products.
This result rules out the possibility that the ﬂuorescence
enhancement in the above assays could be produced by (i)
mere protein–nucleic acid binding or (ii) cleavage of the
DNA strand by a contaminating DNase. The elution proﬁles
also indicated that hRNase-1 cleaves the substrate at a single
site. In this regard, it has to be noted that E.coli RNase H has
a substrate speciﬁcity broader than that of hRNase-1 and most
likely cleaves the ﬂuorogenic substrate at many sites. Since
cleavage at any of these sites will result in ﬂuorescence
enhancement, the true kcat/Km value is probably lower than
that listed in Table 1, and the catalytic efﬁciency of hRNase-
1 may actually be closer to that of the E.coli enzyme.
For comparative purposes, the ribonucleolytic activity
of hRNase-1 toward the isolated RNA strand of the
substrate was also evaluated. Assays were performed by an
HPLC method similar to the one originally described for
human RNase-4 (32) and yielded a kcat/Km of 1 360 000 ±
70 000 M
 1 s
 1. This value is  4-fold higher than that
obtained, under the same reaction conditions, with the
RNA:DNA hybrid, implying that the activity toward this
substrate is only 4-fold lower than that measured with the
ssRNA. With reference to the activity of hRNase-1
toward dsRNA, a direct comparison of the activities toward
poly(rA):poly(rU) and poly(rU), under the same reaction
conditions, has in our knowledge never been reported. How-
ever, the speciﬁc activity of hRNase-1 toward dsRNA from f2
sus11 bacteriophage is known to be  170-fold lower than
that measured with the corresponding ssRNA obtained by
thermal denaturation (9). It should also be noted that the
Figure 3. Cleavage of the substrate by E.coli RNase H. Assays were performed at 37 C in 40 mM Tris–HCl (pH 7.4), containing 60 mM NaCl, 60 mM KCl, 2 mM
MgCl2,4mMDTT,20mg/mlBSAand10nMsubstrate.Fluorescenceintensitywasmeasuredat520nmuponexcitationat490nm.Leftpanelshowsrepresentative
reaction progress curves obtained with 28 pM (b), 100 pM (c) and 140 pM (d) E.coli RNase H. The lowest trace (a) was obtained from a control reaction without
enzyme. Right panel shows the initial rates of substrate cleavage as a function of the concentration of E.coli RNase H.
Table 1. Hybridase activity of various enzymes
Enzyme kcat/Km (M
 1 s
 1 · 10
 3) Relative activity
E.coli RNase H 2540 ± 250 1411
RNase A 1.8 ± 0.2 1
hRNase-1 330 ± 10 183
Reaction conditions were as detailed in Figures 3 and 4. Data are the mean ±
SEM of 6–11 measurements.
Nucleic Acids Research, 2006, Vol. 34, No. 10 2909absolute value of kcat/Km for cleavage of the ﬂuorogenic
RNA:DNA hybrid reported in this article is >2-fold higher
than that measured with poly(rA):poly(rU) (9).
Overall, the data reported above show that hRNase-1 is
endowed with a ribonuclease H activity whose potency is
in the same order of magnitude of that of E.coli RNase H.
Characterization of the hybridase activity of hRNase-1
An attempt to measure individually the kinetic parameters kcat
and Km of hRNase-1 was performed by testing the enzyme at
substrate concentrations between 20 and 400 nM. As shown
in Figure 6, a linear correlation between V0 and [S] was
obtained. This result indicates that the enzyme active site is
poorly saturated at the substrate concentration tested, suggest-
ing that the Km of hRNase-1 for the double-helical hybrid is
higher than 1 mM. This implies that the afﬁnity for the sub-
strate of hRNase-1 is lower than that of E.coli RNase H,
whose Km values for similar substrates are in the nM range.
Nevertheless, the hybridase activity of hRNase-1 is expected
to be highly effective even at low substrate concentration due
to the relatively high kcat/Km value. For comparative pur-
poses, the antimicrobial hRNase-3 and hRNase-7 display
kcat/Km values for cleavage of tRNA of 49 000 and
2 300 000 M
 1 s
 1, respectively, whereas their Km are 1.8
and 2.2 mM, respectively (21). Since these values were
obtained in 40 mM sodium phosphate, pH 7.0, the actual
Km values at physiological ionic strength should be higher.
Taken together, these data suggest that human RNases can
display relevant biological activities also if they have rela-
tively high Km values.
The hybridase activity of hRNase-1 was then tested at
various pHs. As shown in Figure 7, the activity proﬁle is
bell-shaped with a maximum between pH 7 and 7.5. Activit-
ies at pH 8 and 9 are 2- to 20-fold lower than maximal
and that at pH 10 is undetectable. This proﬁle is very similar
Figure4.HybridaseactivityofhRNase-1.Assayswereperformedat37 Cin40mMTris–HCl(pH7.4),containing60mMNaCl,60mMKCl,20mg/mlBSAand10
nMsubstrate.Leftpanelshowsrepresentativereactionprogresscurvesobtainedwith1.8nM(b),2.5nM(c),3.2nM(d)and5.7nM(e)hRNase-1.Thelowesttrace(a)
wasobtainedfromacontrolreactionwithoutenzyme.Inthissetofassays,themaximumchangeinfluorescenceintensity,obtainedbyincubationwithalargeexcess
of hRNase-1, was 380 fluorescence units. Right panel shows the initial rates of substrate cleavage as a function of concentration of hRNase-1.
Figure 5. Reaction products of hRNase-1. RNA:DNA hybrid (0.3 nmol) was
incubatedin30mlof40mMTris–HCl(pH7.4)containing60mMNaCl,60mM
KCl,20mg/mlBSAand3nMhRNase-1.After1hincubationat37 C,reaction
products were analyzed by ion-pair reversed-phase HPLC under fully denatur-
ingconditions(lowerpanel).Traceinupperpanelwasobtainedwithanaliquot
of the undigested hybrid. D and R refer to the DNA and RNA strand of the
hybrid,respectively.TheseassignmentswereobtainedbyHPLCanalysisofthe
individual strandsof the substrate. R3 and R9 refer to the 3 nt and the 9 nt RNA
fragments deriving from the cleavage of the RNA strand, respectively. Figure 6. Michaelis–Menten plot for cleavage of the double-helical substrate
by hRNase-1. Assays were performed as detailed in Figure 4, except that
substrate concentration was 20–400 nM and enzyme concentration was
0.14–1.4 nM.
2910 Nucleic Acids Research, 2006, Vol. 34, No. 10to the one obtained with poly(rA):poly(rU), which is also
bell-shaped with an activity maximum between pH 7 and
7.5 (33). This result shows that hRNase-1 is suited to perform
its hybridase activity under physiological pH conditions, and
suggests that hRNase-1 will digest double-helical substrates
in human plasma better than in duodenum which exhibits
pH values between 5 and 6 (34).
Human RNase-1 was then assayed in solutions at various
ionic strengths. As shown in Table 2, the hybridase activity
is highly dependent on the salt concentration. Activity at
270 mM is in fact 68-fold lower than that measured at
150 mM, and the activity at 30 mM is 94-fold higher than
that measured at 150 mM. This activity proﬁle is quite diff-
erent from those exhibited by hRNase-1 for cleavage of
single-stranded substrates and poly(rA):poly(rU). These are
bell-shaped with activity maxima at 80 and 150 mM for
poly(rA):poly(rU) and poly(rC), respectively (33). In con-
trast, the activity toward the RNA:DNA hybrid has a plateau
at 30–90 mM and sharply decreases when the ionic strength is
raised to 150 mM. This result may be explained by assuming
that the binding of the substrate to the enzyme relies on mul-
tiple salt bridges that are known to be strongly affected by the
ionic strength. These interactions may involve the negatively
charged phosphates of the nucleic acid and some of the basic
residues of the enzyme. An alternative explanation may be
given by taking into account the stability of the double-
helical substrate. It is well known that double helices are
more stable at high ionic strength. Then, the increased
activity of hRNase-1 at low ionic strength may be due to a
lower stability of the substrate and to transiently exposed
ssRNA. However, this interpretation is in contrast with the
observation that the background ﬂuorescence of the undi-
gested substrate was the same at all the ionic strengths tested
(data not shown), indicating that even at 30 mM salt concen-
tration the substrate was stably double-stranded. This aspect
was further inquired by measuring the Tm of the substrate
at 30 and 150 mM salt concentration. The value of Tm at
150 mM resulted to be 61.8 C (Table 2), implying that the
assays at 37 C were performed at a temperature of 25 C
below the Tm. The Tm at 30 mM was found to be 58.1 C, a
value only 3.7 C below the one measured at 150 mM salt.
These results indicate that the stability of the substrate
doesn’t change much in the 30–150 mM range of ionic
strength. Finally, if the increased activity at low ionic
strength was due to a lower stability of the substrate and to
transiently exposed ssRNA, then the activity of RNase A
(that is highly speciﬁc for ssRNA) with lowering salt concen-
tration should increase equally or even more markedly than
observed with hRNase-1. In contrast, the activity of RNase
A at 90 mM salt was found to be only 27-fold higher that
than measured at 150 mM (Table 2), whereas the activity
of hRNase-1 had increased by 97-fold. This makes the activ-
ity of hRNase-1 at 90 mM salt 685-fold higher than that of
RNase A. Similar results were obtained from assays with
RNase A at 30 and 210 mM salt (Table 2). Taken together,
these data suggest that the markedly increased activity of
hRNase-1 registered at low ionic strength is not due to a
lower stability of the double-helical substrate but to a more
effective substrate binding capability. It should also be
noted that the hybridase activity of hRNase-1 does not change
much when the salt concentration is raised from 150 to 210
mM, whereas it decreases rapidly when the ionic strength is
increased to 270 mM (Table 2). The reasons for this second
drop in activity with raising ionic strength (the ﬁrst one was
registered between 90 and 150 mM salt) are unknown and
may also reﬂect possible effects of the high salt concentration
on the catalytic efﬁciency of the enzyme. The data above also
indicate that the hybridase activity of hRNase-1 can be more
conveniently assayed at 90 mM salt. At this ionic strength the
assay is, in fact, about 100-fold more sensitive than at 150
mM salt, making it possible to test hRNase-1 concentrations
as low as 10 pM without affecting speciﬁcity.
Finally, the enzymatic activity of hRNase-1 was tested in
the presence of the human cytosolic RNase inhibitor (cRI),
a 50 kDa protein that binds tightly to most pancreatic-type
RNases and inhibits competitively their ribonucleolytic activ-
ity with Ki values in the fM range (35). Human RNase-1 has
already been reported to be inhibited by cRI and its Ki for
Figure 7. Influence of pH on the hybridase activity of hRNase-1. Assays were
performed at 37 C in a multicomponent buffer system containing 50 mM
sodium acetate, 50 mM 2-(4-Morpholino)ethanesulfonic acid (Mes), 50 mM
4-(2-Hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES), 50 mM 2-
Cyclohexylaminoethanesulphonic acid (Ches), 20 mg/ml BSA and 10 nM
substrate, titrated at the indicated pH.
Table 2.. Effect of ionic strength on hybridase activity and Tm of the double-
helical substrate
Ionic strength (mM) V0/[E]( s
 1 · 10
6) with Tm ( C)
hRNase-1 RNase A
30 178 000 ± 12 000 390 ± 40 58.1
90 185 000 ± 19 000 270 ± 10
150 1900 ± 100 10 ± 1 61.8
210 1200 ± 100 5.4 ± 0.4
270 28 ± 2 ND
Hybridaseassayswereperformedat37 Cin40mMTris–HCl(pH7.4)contain-
ing 20 mg/ml BSA, 10 nM substrate and variable concentrations of NaCl.
Enzyme concentrations were 0.02–100 nM and 0.01–1.2 mM for the human
andbovineenzyme,respectively.Activityvaluesarethemean±SEMofthreeto
fourmeasurements.ValuesofTmwereobtainedfromthermaltransitionprofiles
obtained by raising the temperature of undigested reactionmixtures from 22 to
82 Covera90minperiod.EachTmisthemeanoftwovaluesdeviatingfromthe
mean by <0.6%. ND, not detectable.
Nucleic Acids Research, 2006, Vol. 34, No. 10 2911cleavage of the dinucleotide CpA at pH 6.0 has a value of 200
fM (36). With regard to the hybridase activity, a 2-fold molar
excess of cRI upon hRNase-1 resulted in a complete inhibi-
tion of its enzymatic activity (Figure 8).
CONCLUSIONS
The data reported represent the ﬁrst evidence that hRNase-1
is endowed with a ribonuclease H activity. The kcat/Km value
of the human enzyme, measured under physiological-like
conditions, is 330 000 M
 1 s
 1, a value that is 180-fold
higher than that of bovine pancreatic RNase A and only 8-
fold lower than that measured with E.coli RNase H, the
best characterized member of the RNase H superfamily
(23,24,31). The hybridase activity of hRNase-1 is maximal
at neutral pH, increases with lowering ionic strength and is
fully inhibited by the cytosolic RNase inhibitor.
Since RNA:DNA hybrids represent key intermediates of
replication of retrovirus, the reported data provide a possible
explanation for the anti-HIV activity that hRNase-1 displays
in vitro (22) and thereby support a possible role in human
antiviral defence, as already proposed (9,11). During evolu-
tion, hRNase-1 may have conserved the ability to cleave efﬁ-
ciently ssRNA and to be expressed in exocrine pancreas, as
bovine RNase A, in response to the needing to digest dietary
RNA. At the same time, hRNase-1 has differentiated from the
bovine enzyme by acquiring a strong catalytic activity toward
dsRNA and RNA:DNA hybrids. These enzymatic properties,
together with an expression pattern broader than that of
RNase A (10,12), may constitute the basis for a newly
acquired biological function related to antiviral host defence.
Finally, it should be noted that the availability of a highly
sensitive and speciﬁc assay for the hybridase activity of
hRNase-1 provides the basis for the development of a new
method for the determination of the blood plasma levels of
hRNase-1. In this regard, preliminary tests have shown that
the blood enzyme can be detected by assaying amount of
plasma as little as 1–2 ml (data not shown). The reﬁnement
of this assay should hence provide with an additional tool
the ongoing studies on hRNase-1 as a possible marker of
pathological conditions associated with injury to the vascular
system (11) and to the pancreas (37–39).
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